ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Para, Michael F., Meehan, Patricia, Holden-Wiltse, Jeanne, Fischl, Margaret, Morse, Gene, Shafer, Robert, Demeter, Lisa M., Wood, Kenneth, Nevin, Tom, Virani-Ketter, Nzeera, Freimuth, William W.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 1999
Soggetti:	Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89281/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10348755/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.6.1373
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!